| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1/2 data readout example | ST-503 (investigational epigenetic regulator) Intractable pain due to idiopathic small fiber neuropathy (iSFN) Fast Track | Phase 1/2 | — | Subscribe to access the data. | Small Molecules | Nervous System | |
Phase 1/2 data readout example | ST-503 (investigational epigenetic regulator) Intractable pain due to idiopathic small fiber neuropathy (iSFN) Fast Track | Phase 1/2 | — | Subscribe to access the data. | Small Molecules | Nervous System | |
Phase 1/2 data readout example | ST-503 (investigational epigenetic regulator) Intractable pain due to idiopathic small fiber neuropathy (iSFN) Fast Track | Phase 1/2 | — | Subscribe to access the data. | Small Molecules | Nervous System |
Recent Updates
Recently added Catalysts
Sangamo Therapeutics, Inc.
$0.1
+0.02 (+10.33%)
D 39Pipeline Score Fair Value Biotech · Clinical
Market Cap
73.58 M
EPS
-0.44
P/E Ratio
-
Value Trade
211.20 K
-3.11 %
Week
-29.07 %
1 Month
-60.87 %
3 Month
-67.41 %
6 Month
-98.42 %
5 Year
-98.82 %
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
2.27 M
52 Week Range
0.12 - 0.77
% held by Insiders
2.15 %
% held by Institutions
15.14 %
Enterprise Value
79.42 M
Total Shares
336.39 M
Short %
7.64 %
Float Shares
324.28 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2026-03-31 | Isaralgagene civaparvovec (ST-920) | BLA Submission | BLA | — | – | – | – |
2026-03-31 | Isaralgagene civaparvovec (ST-920) | BLA Submission | BLA | — | – | – | – |
2026-03-31 | Isaralgagene civaparvovec (ST-920) | BLA Submission | BLA | — | – | – | – |
Drug Pipeline Intelligence
D39
Pipeline Score $65M
Pipeline ValueFair Value
Valuation Signal7
Drugs Scored0.9x
rNPV / MCap Top 60%
Micro Cap (rank 374 of 933)
Percentile RankSangamo Therapeutics, Inc. faces pipeline headwinds (39/100), with $4.9B risk-adjusted pipeline value, led by SB-509 in Diabetes Mellitus, Type 1 (Phase 2), across $194B in total addressable markets, but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SB-509 Small molecule | Diabetes Mellitus, Type 1 | Phase 2 | NCT01079325 | 11% | $4.1B | COMPLETED | 394 | - | - | Apr 1, 2016 | - | May 23, 2022 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
isaralgagene civaparvovec | Fabry disease | Phase 1/2 | 2026-02-04 | mean annualized e GFR slope: 1.965 mL/min/1.73m2/year; confidence interval: -0.153, 4.083; mean annualized e GFR slope 104 weeks: 1.747 mL/min/1.73m2/year; confidence interval 104 weeks: -0.106, 3.601 Read More | Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium™ 2026 Read More | |
isaralgagene civaparvovec | Fabry disease | Phase 1/2 | 2026-02-04 | mean annualized e GFR slope: 1.965 mL/min/1.73m2/year; confidence interval: -0.153, 4.083; mean annualized e GFR slope 104 weeks: 1.747 mL/min/1.73m2/year; confidence interval 104 weeks: -0.106, 3.601 Read More | Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium™ 2026 Read More | |
isaralgagene civaparvovec | Fabry disease | Phase 1/2 | 2026-02-04 | mean annualized e GFR slope: 1.965 mL/min/1.73m2/year; confidence interval: -0.153, 4.083; mean annualized e GFR slope 104 weeks: 1.747 mL/min/1.73m2/year; confidence interval 104 weeks: -0.106, 3.601 Read More | Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium™ 2026 Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in SGMO
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
SGMO Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How SGMO ranks across every disease it competes inCompetitive Position is a premium feature
See how SGMO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial